News for Veracyte, Inc. (VCYT)

On March 4, 2025, Phillip Febbo, Chief Scientific & Medical Officer at Veracyte Inc's subsidiary, sold 8,037 shares of Veracyte Inc (VCYT). Following this trans

Veracyte Inc's genomic diagnostics expertise positions it at the forefront of personalized cancer care.Strong intellectual property portfolio and innovative di

Shares of Veracyte Inc (VCYT) surged 3.52% in mid-day trading on Feb 28. The stock reached an intraday high of $35.16, before settling at $35.02, up from it

Despite a solid long-term growth story and strong cash reserves, the high VCYT stock valuation suggests a "hold" rating until profitability trends stabilize. Read more here.

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

Q4 Revenue: $118.6 million, a 21% increase year-over-year.Full Year Revenue: $446 million, a 23% increase year-over-year.Testing Revenue: $112.2 million in Q4,

Feb 24, 2025 / 09:30PM GMTOperator Good day, and thank you for standing by. Welcome to the Veracyte fourth quarter and full year 2024 financial results webcast.

Veracyte, Inc. (NASDAQ:VCYT) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ETCompany ParticipantsShayla Gorman - Senior Director of Investor...

The following slide deck was published by Veracyte, Inc.

Veracyte (VCYT) delivered earnings and revenue surprises of 24.14% and 1.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. ”œI'm incredibly proud of what

VCYT stays on investors radar due to the strong performance of the Afirma and Decipher franchises.

Shares of Veracyte Inc (VCYT) surged 4.03% in mid-day trading on Feb 14. The stock reached an intraday high of $41.42, before settling at $41.19, up from it

Veracyte Inc (VCYT), a prominent cancer diagnostics company, announced significant findings at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. T

Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, February 13th: Veracyte, Inc. VCYT: This diagnostics company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 20.4% over the last 60 days.

On December 31, 2024, Artisan Partners Limited Partnership (Trades, Portfolio) executed a significant stock transaction, adding 1,576,432 shares of Veracyte Inc

Shares of Veracyte Inc (VCYT) fell 3.52% in mid-day trading on Feb 6. The stock reached an intraday low of $43.23, before recovering slightly to $43.61, dow

On February 3, 2025, Rebecca Chambers, the Chief Financial Officer of Veracyte Inc (VCYT), sold 527 shares of the company. Following this transaction, the insid

Shares of Veracyte Inc (VCYT) surged 5.67% in mid-day trading on Jan 21. The stock reached an intraday high of $42.95, before settling at $42.88, up from it